A metagenomic study of the gut microbiome in Behcet's diseaseOriginal paper
Karen Pendergrass is a microbiome researcher specializing in microbiome-targeted interventions (MBTIs). She systematically analyzes scientific literature to identify microbial patterns, develop hypotheses, and validate interventions. As the founder of the Microbiome Signatures Database, she bridges microbiome research with clinical practice. In 2012, based on her own investigative research, she became the first documented case of FMT for Celiac Disease, four years before the first published case study.
Read MoreWhat was studied?
This study examined the gut and oral microbiome in Behcet's disease (BD), a recurring inflammatory disease that can cause irreversible blindness. Researchers used metagenomic sequencing of fecal samples and 16S rRNA gene sequencing of saliva samples to compare microbial composition and biological function between BD patients and healthy controls. They then transplanted pooled fecal samples from active BD patients into mice undergoing experimental autoimmune uveitis (EAU) to test whether the gut microbiome could causally influence disease development.
Who was studied?
The human cohort consisted of 32 patients with active Behcet's disease and 74 healthy controls, who each provided fecal and saliva samples. The animal component of the study used B10RIII mice with induced experimental autoimmune uveitis, a model used to study the eye inflammation seen in BD. Together these groups allowed comparison of microbial signatures in humans alongside a causal test in an animal model.
What were the most important findings?
Fecal samples from active BD patients were enriched in Bilophila species, a sulfate-reducing bacteria (SRB), along with several opportunistic pathogens including Parabacteroides and Paraprevotella species. This enrichment occurred alongside a lower level of butyrate-producing bacteria compared to healthy controls. These shifts point to a gut microbial imbalance involving sulfate-reducing organisms and reduced beneficial short-chain fatty acid producers in BD patients.
What are the greatest implications of this study?
The findings suggest that gut microbiome composition, particularly the expansion of sulfate-reducing bacteria like Bilophila and the loss of butyrate producers, may contribute to the inflammatory processes underlying Behcet's disease. Using fecal transplantation into an autoimmune uveitis mouse model supports the idea that the gut microbiome may play a causal role rather than simply reflecting disease state. This work highlights the gut microbiome, and specifically sulfate-reducing and butyrate-producing bacteria, as a potential target for understanding or managing BD-related inflammation.